While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Senators on the Health, Education, Labor, and Pensions committee were critical of Kennedy’s long history as an anti-vaccine campaigner.

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

While the Chicago metropolitan area is not a major life sciences hub, a recent Cushman & Wakefield report predicts the ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.